Welcome!

News Feed Item

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

LONDON, Sept. 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703975/Coronary-Arteriosclerosis-Global-Clinical-Trials-Review-H2-2014.html

Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014" provides data on the Coronary Arteriosclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Coronary Arteriosclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Coronary Arteriosclerosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Coronary Arteriosclerosis 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Coronary Arteriosclerosis 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Coronary Arteriosclerosis Therapeutics Clinical Trials 29
Prominent Drugs 30
Clinical Trial Profiles 31
Clinical Trial Overview of Top Companies 31
Pfizer Inc. 31
Clinical Trial Overview of Pfizer Inc. 31
Merck & Co., Inc. 32
Clinical Trial Overview of Merck & Co., Inc. 32
Eli Lilly and Company 33
Clinical Trial Overview of Eli Lilly and Company 33
Cytori Therapeutics, Inc. 34
Clinical Trial Overview of Cytori Therapeutics, Inc. 34
C. H. Boehringer Sohn AG & Co. KG 35
Clinical Trial Overview of C. H. Boehringer Sohn AG & Co. KG 35
AstraZeneca PLC 36
Clinical Trial Overview of AstraZeneca PLC 36
MDDX LLC 37
Clinical Trial Overview of MDDX LLC 37
Innovaderm Research Inc. 38
Clinical Trial Overview of Innovaderm Research Inc. 38
CardioVascular BioTherapeutics, Inc. 39
Clinical Trial Overview of CardioVascular BioTherapeutics, Inc. 39
Avant Immunotherapeutics, Inc 40
Clinical Trial Overview of Avant Immunotherapeutics, Inc 40
Clinical Trial Overview of Top Institutes / Government 41
National Heart, Lung, and Blood Institute 41
Clinical Trial Overview of National Heart, Lung, and Blood Institute 41
Providence VA Medical Center 42
Clinical Trial Overview of Providence VA Medical Center 42
National Taiwan University Hospital 43
Clinical Trial Overview of National Taiwan University Hospital 43
Seoul National University Hospital 44
Clinical Trial Overview of Seoul National University Hospital 44
Rigshospitalet 45
Clinical Trial Overview of Rigshospitalet 45
University of Ottawa Heart Institute 46
Clinical Trial Overview of University of Ottawa Heart Institute 46
University of California, San Diego 47
Clinical Trial Overview of University of California, San Diego 47
University of Minnesota 48
Clinical Trial Overview of University of Minnesota 48
Massachusetts General Hospital 49
Clinical Trial Overview of Massachusetts General Hospital 49
U.S. Department of Veterans Affairs 50
Clinical Trial Overview of U.S. Department of Veterans Affairs 50
Five Key Clinical Profiles 51
Appendix 81
Abbreviations 81
Definitions 81
Research Methodology 82
Secondary Research 82
About GlobalData 83
Contact Us 83
Disclaimer 83
Source 83

List of Tables
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Region, 2014* 7
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Coronary Arteriosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Coronary Arteriosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Coronary Arteriosclerosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Coronary Arteriosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Coronary Arteriosclerosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Coronary Arteriosclerosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Coronary Arteriosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 31
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 32
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 33
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytori Therapeutics, Inc., 2014* 34
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG & Co. KG, 2014* 35
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 36
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by MDDX LLC, 2014* 37
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Innovaderm Research Inc., 2014* 38
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by CardioVascular BioTherapeutics, Inc., 2014* 39
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Avant Immunotherapeutics, Inc, 2014* 40
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 41
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Providence VA Medical Center, 2014* 42
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 43
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Seoul National University Hospital, 2014* 44
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Rigshospitalet, 2014* 45
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Ottawa Heart Institute, 2014* 46
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Diego, 2014* 47
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Minnesota, 2014* 48
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 49
Coronary Arteriosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by U.S. Department of Veterans Affairs, 2014* 50

List of Figures
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Coronary Arteriosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Coronary Arteriosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Coronary Arteriosclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Coronary Arteriosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Coronary Arteriosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Coronary Arteriosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Coronary Arteriosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Coronary Arteriosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Coronary Arteriosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 27
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Coronary Arteriosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30
GlobalData Methodology 82

Read the full report:
Coronary Arteriosclerosis Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/703975/Coronary-Arteriosclerosis-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex softw...
Internet of @ThingsExpo, taking place June 6-8, 2017 at the Javits Center in New York City, New York, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo New York Call for Papers is now open.
In his session at 19th Cloud Expo, Claude Remillard, Principal Program Manager in Developer Division at Microsoft, contrasted how his team used config as code and immutable patterns for continuous delivery of microservices and apps to the cloud. He showed how the immutable patterns helps developers do away with most of the complexity of config as code-enabling scenarios such as rollback, zero downtime upgrades with far greater simplicity. He also demoed building immutable pipelines in the cloud ...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
SYS-CON Events announced today that Catchpoint Systems, Inc., a provider of innovative web and infrastructure monitoring solutions, has been named “Silver Sponsor” of SYS-CON's DevOps Summit at 18th Cloud Expo New York, which will take place June 7-9, 2016, at the Javits Center in New York City, NY. Catchpoint is a leading Digital Performance Analytics company that provides unparalleled insight into customer-critical services to help consistently deliver an amazing customer experience. Designed ...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
While many government agencies have embraced the idea of employing cloud computing as a tool for increasing the efficiency and flexibility of IT, many still struggle with large scale adoption. The challenge is mainly attributed to the federated structure of these agencies as well as the immaturity of brokerage and governance tools and models. Initiatives like FedRAMP are a great first step toward solving many of these challenges but there are a lot of unknowns that are yet to be tackled. In hi...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...
The proper isolation of resources is essential for multi-tenant environments. The traditional approach to isolate resources is, however, rather heavyweight. In his session at 18th Cloud Expo, Igor Drobiazko, co-founder of elastic.io, drew upon his own experience with operating a Docker container-based infrastructure on a large scale and present a lightweight solution for resource isolation using microservices. He also discussed the implementation of microservices in data and application integrat...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...